Kyntra Bio (KYNB)
NASDAQ:KYNB
Top Page
Kyntra Bio
(NASDAQ:KYNB)
Select Model
Select Model
Rating:49Neutral
Price Target:
$7.50
▲(5.93% Upside)
Action:ReiteratedDate:04/10/26
The score is held down primarily by weak financial performance (collapsed revenue, persistent operating losses, and ongoing negative free cash flow), with additional pressure from a still-negative longer-term technical trend and the Nasdaq compliance overhang. These are partially offset by a cleaner balance sheet (debt reduced to zero), a cash runway into 2028 and cost reductions discussed on the earnings call, and optically inexpensive valuation based on the very low P/E.
Positive Factors
Debt elimination
Eliminating outstanding debt materially reduces refinancing and interest-rate risk, lowering fixed obligations and preserving cash for R&D and trials. A zero-debt balance sheet increases strategic optionality for partnering or trial funding and strengthens survivability over the next 2–6 months.
Negative Factors
Collapsed revenue
A dramatic revenue decline erodes internal capacity to fund operations and weakens negotiating leverage with partners. With commercial/licensing income largely gone, the company is structurally reliant on clinical readouts, external funding, or asset sales to rebuild sustainable revenues over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt elimination
Eliminating outstanding debt materially reduces refinancing and interest-rate risk, lowering fixed obligations and preserving cash for R&D and trials. A zero-debt balance sheet increases strategic optionality for partnering or trial funding and strengthens survivability over the next 2–6 months.
Read all positive factors
Kyntra Bio (KYNB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$29.02M
Dividend YieldN/A
Average Volume (3M)30.76K
Price to Earnings (P/E)0.2
Beta (1Y)0.96
Revenue Growth-95.39%
EPS GrowthN/A
CountryUS
Employees225
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)-3.51
Shares Outstanding4,046,827
10 Day Avg. Volume33,010
30 Day Avg. Volume30,760
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)7.93
Price to Sales (P/S)5.51
P/FCF Ratio-7.38
Enterprise Value/Market Cap-0.62
Enterprise Value/Revenue-2.80
Enterprise Value/Gross Profit-3.70
Enterprise Value/Ebitda0.39
Forecast
1Y Price Target
$25.00Price Target Upside253.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-11.95
Revenue Forecast (FY)$6.10M
Kyntra Bio Business Overview & Revenue Model
Company Description
Kyntra Bio, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines ...
How the Company Makes Money
null...
Kyntra Bio Key Performance Indicators (KPIs)
Any
Revenue by Segment
Analyzes revenue from different business areas, highlighting which segments drive growth and profitability, and identifying potential areas of strength or concern.
Analyzes revenue from different business areas, highlighting which segments drive growth and profitability, and identifying potential areas of strength or concern.
Data provided by:
The Fly
The FlyKyntra Bio Earnings Call Summary
Earnings Call Date:Mar 16, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 11, 2026
Earnings Call Sentiment Neutral
The call emphasizes substantial balance-sheet strengthening (sale, debt paydown), large full-year cost reductions, a clear cash runway into 2028, and encouraging early clinical signals for FG-3246/FG-3180 plus a promising roxadustat signal with orphan designation. However, the company faces sharp revenue declines, a weaker Q4 operating/profitability profile, statistical uncertainty around the imaging biomarker, dependency on upcoming trial readouts (2026–2027), and unresolved partnering/commercial strategies. Overall, the positives center on financing and promising early clinical data, while significant operational and commercialization uncertainties remain.Positive Updates
Transformational Corporate Actions and Strengthened Balance Sheet
Completed sale of FibroGen China to AstraZeneca, paid off senior secured term loan, and extended cash runway into 2028. Reported cash, cash equivalents, investments, and accounts receivable of $109.4M as of 12/31/2025.
Negative Updates
Sharp Revenue Declines
Revenue fell markedly: Q4 2025 revenue $1.3M vs $3.1M in Q4 2024 (-58.1%), and FY2025 revenue $6.4M vs $29.6M in FY2024 (-78.4%), reflecting significantly lower topline commercial/licensing contributions post-transaction.
Read all updates
Q4-2025 Updates
Positive
Negative
Transformational Corporate Actions and Strengthened Balance Sheet
Completed sale of FibroGen China to AstraZeneca, paid off senior secured term loan, and extended cash runway into 2028. Reported cash, cash equivalents, investments, and accounts receivable of $109.4M as of 12/31/2025.
Read all positive updates
Company Guidance
Kyntra guided that it finished 2025 with $109.4M in cash, cash equivalents, investments and receivables and a cash runway into 2028, and outlined near‑term clinical and regulatory milestones: for FG‑3246/FG‑3180 in mCRPC, IST topline (n=44) showed median rPFS 7.0 months overall and 10.1 months in patients progressed on one prior ARPI with PSA50 = 40% (phase 1 monotherapy rPFS 8.7 months, PSA50 36%); the phase 2 monotherapy trial will enroll 75 post‑ARPI/pre‑chemo patients across three dose levels, incorporate FG‑3180 SUV biomarker analyses (nominal p ~ NS), use G‑CSF prophylaxis to reduce grade ≥3 neutropenia, target an interim readout in 2026 and mature rPFS in 2027 with a commercial rPFS benchmark ≥10 months and a U.S. TAM >$5B; for roxadustat, target population ≈49,000 U.S. patients, MATTERHORN high‑transfusion subgroup showed 36% transfusion independence ≥8 weeks vs 7% placebo (p=0.041), orphan designation (≈7 years exclusivity), FDA protocol feedback expected in the coming weeks (60–90 days) and phase 3 initiation targeted in H2 2026; FY2025 revenue was $6.4M (Q4 $1.3M), total operating expenses $52.3M, R&D $23.5M, SG&A $27.7M, and net loss $58.2M ($14.40/share).Kyntra Bio Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
28
Negative
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 6.44M | 29.62M | 46.80M | 140.73M | 235.31M |
| Gross Profit | 0.00 | 14.06M | 42.84M | 120.45M | -213.88M |
| EBITDA | -45.90M | -142.43M | -305.20M | -282.82M | -333.72M |
| Net Income | 183.45M | -47.58M | -284.23M | -293.65M | -290.02M |
Balance Sheet | |||||
| Total Assets | 119.59M | 214.53M | 423.53M | 610.09M | 773.82M |
| Cash, Cash Equivalents and Short-Term Investments | 88.98M | 50.48M | 235.59M | 422.01M | 405.19M |
| Total Debt | 0.00 | 90.17M | 170.46M | 89.89M | 99.72M |
| Total Liabilities | 115.12M | 398.16M | 585.73M | 611.57M | 544.71M |
| Stockholders Equity | 4.47M | -225.60M | -204.17M | -21.45M | 209.15M |
Cash Flow | |||||
| Free Cash Flow | -4.81M | -138.26M | -317.54M | -184.67M | -112.42M |
| Operating Cash Flow | -4.77M | -138.00M | -315.02M | -145.93M | -82.23M |
| Investing Cash Flow | 35.42M | 125.99M | 153.66M | 89.12M | -426.97M |
| Financing Cash Flow | -86.03M | -255.00K | 122.75M | 46.78M | -563.00K |
Kyntra Bio Technical Analysis
Neutral
7.08
Price Trends
7.28
Negative
8.01
Negative
8.88
Negative
Market Momentum
-0.05
Negative
49.71
Neutral
73.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KYNB, the sentiment is Neutral. The current price of 7.08 is above the 20-day moving average (MA) of 6.98, below the 50-day MA of 7.28, and below the 200-day MA of 8.88, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 49.71 is Neutral, neither overbought nor oversold. The STOCH value of 73.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for KYNB.
Kyntra Bio Risk Analysis
Kyntra Bio disclosed 56 risk factors in its most recent earnings report. Kyntra Bio reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Kyntra Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $58.80M | -0.66 | -115.64% | ― | ― | 46.20% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $29.02M | 0.19 | ― | ― | -95.39% | ― | |
49 Neutral | $49.21M | -21.38 | -311.80% | ― | 588.40% | 61.76% | |
46 Neutral | $55.55M | -4.61 | -10.61% | ― | ― | 45.97% | |
43 Neutral | $27.19M | -0.40 | -197.68% | ― | ― | 78.60% |
* Healthcare Sector Average
KYNB
Kyntra Bio
7.08
-0.33
-4.39%
GRCE
Grace Therapeutics
3.82
1.66
76.85%
OKUR
OnKure Therapeutics
4.45
1.45
48.33%
SNTI
Senti Biosciences
0.90
-2.77
-75.45%
XLO
Xilio Therapeutics
8.46
-1.51
-15.13%
Kyntra Bio Corporate Events
Business Operations and StrategyDelistings and Listing ChangesFinancial DisclosuresRegulatory Filings and Compliance
Kyntra Bio Faces Nasdaq Compliance Challenge After Revenue Shift
Negative
Apr 9, 2026
On April 2, 2026, Kyntra Bio, Inc. disclosed it had received a notice from Nasdaq stating the company no longer complies with the Nasdaq Global Select Market requirement for $50 million in total assets and total revenue for the most recently compl...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.